rss
Arch Dis Child 2009;94:132-137 doi:10.1136/adc.2008.141820
  • Original article

Prevention and treatment of renal disease in Henoch-Schönlein purpura: a systematic review

  1. W Chartapisak1,3,
  2. S L Opastiraku3,
  3. N S Willis1,2,
  4. J C Craig1,2,
  5. E M Hodson1,2
  1. 1
    Cochrane Renal Group, Centre for Kidney Research, The Children’s Hospital at Westmead, Sydney, Australia
  2. 2
    School of Public Health, University of Sydney, Sydney, Australia
  3. 3
    Department of Pediatrics, Faculty of Medicine, Chiang Mai University, Chiang Mai, Thailand
  1. Dr E Hodson, Centre for Kidney Research, The Children’s Hospital at Westmead, Locked Bag 4001, Westmead, NSW 2145, Australia; Elisah{at}chw.edu.au
  • Accepted 31 July 2008
  • Published Online First 13 August 2008

Abstract

Objective: To determine the benefits and harms of therapies used to prevent or treat renal involvement in Henoch-Schönlein purpura.

Design: Systematic review of randomised controlled trials.

Setting: Secondary and tertiary paediatric and paediatric nephrology services.

Subjects: Ten trials involving 1230 children aged less than 18 years.

Main outcome measures: Persistent proteinuria and/or haematuria.

Results: Meta-analyses of four trials showed no significant difference in the risk of persistent kidney disease at 6 months (379 children; relative risk (RR) 0.51, 95% CI 0.24 to 1.11) and 12 months (498 children; RR 1.02, 95% CI 0.40 to 2.62) in children given prednisone for 14–28 days at presentation of Henoch-Schönlein purpura compared with placebo or supportive treatment. In children with severe renal disease, there was no significant difference in the risk of persistent renal disease with cyclophosphamide compared with supportive treatment (one trial; 56 children; RR 1.07, 95% CI 0.65 to 1.78) and with cyclosporin compared with methylprednisolone (one trial; 19 children; RR 0.39; 95% CI 0.14 to 1.06).

Conclusions: Data from randomised trials for any intervention used to improve renal outcomes in children with Henoch-Schönlein purpura are very sparse except for short-term prednisone, which has not been shown to be effective.

Footnotes

  • Competing interests: None.

This Article

  1. Abstract
  2. Full text
  3. PDF
  4. All versions of this article:
    1. adc.2008.141820v1
    2. 94/2/132 most recent

Responses

  1. Submit a response
  2. No responses published

Register for free content

The full back archive is now available for all BMJ Journals. Institutional subscribers may access the entire archive as part of their subscription. Personal subscribers will also have access to all content when logged in. Non-subscribers who register have free access to all articles published before 2006 right back to volume 1 issue 1. Register here to access the free archive of all BMJ Journals.

Don't forget to sign up for content alerts so you keep up to date with all the articles as they are published.

ADC is co-owned by the RCPCH and is the official journal of the European Academy of Paediatrics

Show me all >>